Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

New clinical predictors required to determine future asthma attacks

Screening tests used to predict asthma activity in patients may have little tracking success when applied to people with persistent disease who are adhering to their health care regimens, UT Southwestern Medical Center physician report.

1 Sep 2009

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on the hospital acute care and gastroenterology markets, today announced second quarter 2009 financial results.

27 Aug 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

Bristol-Myers Squibb Company announced today that clinical data added to the labeling for ORENCIA (abatacept) support use of ORENCIA for patients with moderate to severe rheumatoid arthritis of less than or equal to two years duration.

27 Aug 2009

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

Schering-Plough Corporation, (NYSE: SGP), today announced that the European Medicines Agency (EMEA) has validated (accepted for review) the company's Marketing Authorization Application (MAA) for a fixed-dose combination of mometasone furoate and formoterol fumarate for the maintenance treatment of asthma in patients 12 years of age and older.

27 Aug 2009

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

MedImmune, Women's Professional Soccer (WPS) and the American Youth Soccer Organization (AYSO) today officially launched "Don't Play with the Flu,"((TM)) a national health awareness campaign that aims to highlight the importance of getting a seasonal influenza vaccination every year.

20 Aug 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

CSL Biotherapies to supply Afluria influenza vaccines from newly licensed packaging facility

CSL Biotherapies, a subsidiary of CSL Limited, one of the world's leading manufacturers of influenza vaccine, announced today that the U.S. Food and Drug Administration (FDA) has licensed the company’s newest vaccine filling and packaging facility, located in Kankakee, Ill. The facility, part of an investment to expand CSL’s U.S. influenza vaccine production capabilities, includes a high-speed, single-dose vaccine syringe filling line.

19 Aug 2009

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

CSL Behring announced today that Helixate® FS, Antihemophilic Factor (Recombinant), has been approved by the U.S. Food and Drug Administration (FDA) for routine prophylaxis in children with hemophilia A who are 16 years old or younger and do not have pre-existing joint damage.

17 Aug 2009

Xerostomia linked to use of multiple medications

Approximately ninety-one percent of dentists say patients complaining about dry mouth are taking multiple medications, according to a nationwide member survey conducted by the Academy of General Dentistry (AGD).

9 Jul 2009

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

A chemotherapy drug that is supposed to help save cancer patients' lives, instead resulted in life-threatening and sometimes fatal allergic reactions.

9 Jun 2009

Cimzia approved in U.S. for rheumatoid arthritis

UCB announced today that the U.S. Food and Drug Administration (FDA) approved Cimzia, the only PEGylated anti-TNF (Tumor Necrosis Factor), for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA).

13 May 2009

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

Ferring Pharmaceuticals has announced the launch of a Phase IIIB clinical trial of degarelix for injection, a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer.

27 Apr 2009

FDA grants Oasmia's Paclical orphan drug designation for ovarian cancer in U.S.

Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical for the treatment of ovarian cancer.

14 Apr 2009

Prolonged consumption of sports drinks may be linked to erosive tooth wear

While sipping on sports drinks all day may provide an energy boost, this popular practice is also exposing people to levels of acid that can cause tooth erosion and hypersensitivity, NYU dental researchers have found.

6 Apr 2009

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

Lantheus Medical Imaging, Inc has announced new data regarding the use of DEFINITY Vial For (Perflutren Lipid Microsphere) Injectable Suspension.

29 Mar 2009

Hypersensitivity News and Research

New clinical predictors required to determine future asthma attacks

Cumberland Pharmaceuticals posts $9.8 million revenues for the three months ended June 30, 2009

Clinical data added to ORENCIA labeling help treat patients with rheumatoid arthritis

European Medicines Agency validates Schering-Plough's MAA for nomegestrol acetate/17 beta-estradiol

MedImmune, WPS and AYSO collaboratively launch a national health awareness campaign

Aton Pharma markets preservative-free drugs for glaucoma

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

The Gambia introduces pneumococcal immunisation programme

CSL Biotherapies to supply Afluria influenza vaccines from newly licensed packaging facility

FDA approves Helixate FS for routine prophylaxis in children with hemophilia A

Xerostomia linked to use of multiple medications

Cremophor-based paclitaxel ‘chemo’ drug triggers fatal allergic reactions

Cimzia approved in U.S. for rheumatoid arthritis

Ferring Pharmaceuticals launches new trial of Degarelix for intermittent androgen deprivation therapy

FDA grants Oasmia's Paclical orphan drug designation for ovarian cancer in U.S.

Prolonged consumption of sports drinks may be linked to erosive tooth wear

New Lantheus study finds significant survival benefit for critically ill patients undergoing contrast-enhanced echocardiography

FDA approves Symbyax for treatment-resistant depression

A vaccine for multiple sclerosis

European Commission and US FDA approve intravenous formulation of temozolomide

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News